Core Viewpoint - The company, Shenzhen Beixin Life Technology Co., Ltd., is making significant strides in the high-end medical device sector, particularly in cardiovascular precision intervention, breaking through technological barriers and contributing to global healthcare solutions under the "Healthy China 2030" strategy [1]. Group 1: Technological Breakthroughs - The company has focused on overcoming "bottleneck" technologies in the cardiovascular diagnostic and therapeutic device market, which has been dominated by imported products [2]. - It has successfully developed two core products: the gold standard FFR system and the first 60MHz high-speed IVUS system, enhancing clinical efficiency and accuracy [2]. Group 2: Commercialization and Financial Performance - The company has commercialized 11 products, with core products being used in approximately 1,000 hospitals globally [3]. - Revenue is projected to grow from 92.45 million yuan in 2022 to 317 million yuan in 2024, reflecting a compound annual growth rate of over 85% [3]. - The net cash flow from operating activities is expected to turn positive in 2024, reaching 29.91 million yuan, marking a significant milestone in self-sustainability [3]. Group 3: Research and Development - The company has invested 389 million yuan in R&D from 2022 to 2024, establishing four core technology platforms [4]. - It has developed a comprehensive innovation system that integrates technology research, product development, clinical studies, and commercialization [5]. Group 4: Global Expansion - The company is actively pursuing a high-quality "going global" strategy, with its core products entering markets in Germany, the UK, the Netherlands, and Belgium [3]. - Overseas revenue increased from 5.74 million yuan in 2022 to 38.83 million yuan in 2024, contributing to 12.27% of total revenue [3]. Group 5: Future Prospects - The company is expanding into electrophysiology and is working on pulse field ablation technology to enhance the safety and effectiveness of atrial fibrillation treatments [5]. - It has been recognized as a national-level specialized and innovative "little giant" enterprise, indicating its strong position in the industry [5].